In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Patients with no schooling benefit least from blood thinning medications

Atrial fibrillation patients with low education miss treatment targets more often

Patients with no schooling benefit least from blood thinning medications, reveals a European Heart Rhythm Association (EHRA) / European Society of Cardiology (ESC) survey published today in Europace. The poll of more than 1,100 patients with atrial fibrillation found those with no schooling missed treatment targets more often, were less aware of bleeding risks, and did not know they could continue normal daily activities.

Atrial Fibrillation
Cardiovascular Pharmacotherapy
Diseases of the Aorta, Peripheral Vascular Disease, Stroke

Embargo: 22 February 2016 at 01:15 CET (00:15 GMT)

Sophia Antipolis, 22 February 2016: Patients with no schooling benefit least from blood thinning medications, reveals a European Heart Rhythm Association (EHRA) / European Society of Cardiology (ESC) survey published today in Europace.1 The poll of more than 1100 patients with atrial fibrillation found those with no schooling missed treatment targets more often, were less aware of bleeding risks, and did not know they could continue normal daily activities.

80% of university educated patients knew they could drive, play sports and travel by plane compared to 52% without schooling.

Atrial fibrillation is the most common cardiac rhythm disorder and affects 1.5–2% of the general population in the developed world.2 Atrial fibrillation substantially increases the risk of stroke. When strokes occur in patients with atrial fibrillation they are associated with more death and disability, longer hospital stays, and less chance of returning home.3

EHRA President Professor Gerhard Hindricks said: “Blood thinning medications, also called oral anticoagulants, are the most effective way of preventing strokes in patients with atrial fibrillation and risk factors for stroke. We asked patients what they knew about their drugs and analysed whether this differed by gender, age, education level, and country of residence.”

A total of 1147 patients with atrial fibrillation and taking oral anticoagulation completed 40 questions online. Oral anticoagulation included the vitamin K antagonists (such as warfarin) and the non-vitamin K oral anticoagulants (also called NOACs). Responses were collected over three months. Patients were 66 years old on average and 46% were women. Patients were from eight countries: France (33.6%), Denmark (26.6%), Sweden (20.9%), Spain (7.7%), Norway (4.5%), Germany (3.7%), the UK (2.2%) and Italy (0.8%).

The responses reveal disparities between patients with differing levels of education in terms of the benefits of anticoagulation and knowledge about the medication. Patients taking vitamin K antagonists such as warfarin are advised to keep their international normalised ratio (INR) level, which indicates how long it takes blood to form a clot, between 2 and 3. Patients with no schooling were more likely to exceed the upper limit several times a month than those with college or university education (5.1% vs 2.8%, p<0.05).

Awareness of the bleeding risks associated with anticoagulant drugs was lowest in patients without schooling (38.5%) and highest in those with college and university education (57.0%) (p<0.05). Nearly one in four (23%) patients without schooling reported having bleeding events associated with their medication compared to 18.7% with college and university education. Patients without schooling also had a higher rate of previous stroke (2.6%) than those with college and university education (0.71 %) (p<0.05).

Professor Carina Blomström-Lundqvist, who led the survey and is final author of the paper, said: “The survey shows that differences in patient education level may compromise the safety and efficacy of anticoagulants. Patients unaware of the importance of being compliant have a higher risk for both bleeding events and stroke. The findings underline the importance of providing user-friendly education about risk factors for stroke and adequate use of anticoagulants, and the importance of tailoring the educational message to the target population so that it is understood irrespective of the patient’s level of schooling.”

The impact of anticoagulation on quality of life differed by education level. The majority (80.2%) of patients with university education knew that they could continue their normal daily activities such as travelling by plane, sports, driving a car, or having a job, compared to just 51.8% of patients without schooling (p<0.05). “Patients may be missing out on daily life because they don’t realise they are safe to do sports, travel and other activities, which may explain the lower quality of life observed in many patients with atrial fibrillation,” said Professor Blomström-Lundqvist. “More awareness and education about these issues are needed.”

Taking the patient group as a whole, when asked about the purpose of their anticoagulation medication, the majority (91–94%) correctly understood that it was to “thin the blood” but 6–9% incorrectly said it was to control the arrhythmia. Professor Blomström-Lundqvist said: “The survey demonstrated that a significant percentage of patients (around 8%) did not even understand the purpose of anticoagulation correctly and surprisingly, the number of patients who were aware of NOACs was still quite small.”

She added: “This survey has important implications as it shows not only the need for more education in general about the indication and use of anticoagulants in patients with atrial fibrillation, but importantly also that differences in educational level among patient populations may significantly compromise the safety and efficacy of anticoagulants.”

Professor Blomström-Lundqvist concluded: “We believe that associations and societies like EHRA and the ESC have an important task to provide more user-friendly educational tools to improve knowledge about anticoagulation use – when and how to take it and the importance of taking it - for both atrial fibrillation patients and their physicians. We also need to increase the awareness of NOACs, so that all patients, independent of their educational level, can have access to the most optimal therapy.”4



1Hernández Madrid A, Potpara TS, Dagres N, Chen J, Larsen TB, Estner H, Todd D, Bongiorni MG, Sciaraffia E, Proclemer A, Cheggour S, Amara W, Blomstrom-Lundqvist C. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016. doi:10.1093/europace/euv448
2Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2012;33:2719–2747.
3Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313(19):1950–1962.
4Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. Cardiac tachyarrhythmias and patient values and preferences for their management:  An European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015;17(12):1747–1769.

Notes to editor

ESC Press Office
Tel: +33 (0) 4 92 94 86 27


DISCLOSURES: None related to the topic.

Patient information about atrial fibrillation is available on EHRA’s AFib Matters website

About the European Heart Rhythm Association
The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reduce sudden cardiac death.

About Europace 
EP Europace is the official journal of the European Heart Rhythm Association and the ESC Working Group on Cardiac Cellular Electrophysiology. EP Europace is also an official journal of the ESC Working Group on e-Cardiology. It aims to provide an avenue of communication of top quality European and international original scientific work and reviews in the fields of Arrhythmias, Pacing and Cellular Electrophysiology.

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.